Dare Bioscience

Dare Bioscience Operating Cash Flow

The Operating Cash Flow of Dare Bioscience (DARE) as of Oct 31, 2026 is -9.89 M USD. In the previous year, Operating Cash Flow was 5.39 M USD — a change of -283.27% (lower).

Operating Cash Flow

-9.89 MUSD

YoY

-283.27%

Last updated:

Operating Cash Flow of Dare Bioscience is 2025 -9.89 M USD. Operating Cash Flow of Dare Bioscience was 2024 5.39 M USD. It decreases by -283.27% lower compared to the previous year.

The Dare Bioscience Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-10.27 M USD
Jan 1, 2019
-13.32 M USD
Jan 1, 2020
-25.23 M USD
Jan 1, 2021
-28.76 M USD
Jan 1, 2022
-18.09 M USD
Jan 1, 2023
-38.86 M USD
Jan 1, 2024
5.39 M USD
Jan 1, 2025
-9.89 M USD
The Dare Bioscience Operating Cash Flow history
YEAROperating Cash FlowYoY
-9.89 MUSD-283.27%
5.39 MUSD-113.88%
-38.86 MUSD+114.81%
-18.09 MUSD-37.11%
-28.76 MUSD+13.99%
-25.23 MUSD+89.52%
-13.32 MUSD+29.67%
-10.27 MUSD+304.25%
-2.54 MUSD-92.43%
-33.54 MUSD+5.08%
-31.92 MUSD+67.44%
-19.06 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience Stock analysis

What does Dare Bioscience do? Daré Bioscience, Inc. develops and commercializes pharmaceutical products in women's reproductive health, focusing on non-hormonal contraceptive solutions. Its lead product, Ovaprene, is a clinical stage intravaginal ring designed to provide multi-week protection without intervention during intercourse. The ring features a permeable mesh barrier and localized spermiostatic agent delivery, combining barrier and spermicidal mechanisms to achieve efficacy comparable to diaphragms and short-acting hormonal methods like oral pills and vaginal rings. The company targets women seeking non-hormonal contraceptive options, with Ovaprene positioned as an alternative to existing hormonal products and barrier methods. The firm generates revenue through the development and commercialization of Ovaprene, aiming to address unmet needs in women's reproductive health. Ovaprene is designed to offer a non-hormonal, user-friendly alternative to traditional hormonal contraceptives, appealing to consumers who prefer avoiding hormonal side effects. The company's focus on clinical development and product commercialization aligns with the market demand for innovative, non-hormonal contraceptive options in women's health. Dare Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dare Bioscience stock

Operating Cash Flow of Dare Bioscience is -9.89 M USD in 2025.

Operating Cash Flow of Dare Bioscience changed from 5.39 M USD to -9.89 M USD, representing a -283.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Dare Bioscience since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Dare Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Dare Bioscience

All Key Metrics — Dare Bioscience